Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View

Dr. Sara Dong

Transplant/Immunocompromised States · Boston Children's Hospital

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Keith Kaye

General ID · RU

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Kelly Dooley

Mycobacterial Disease · Vanderbilt

View

Dr. Erin Bonura

General ID · OHSU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Assessing the safety of increased outpatient cephalosporin use following the modification of penicillin allergy cross-reactivity alerts.

    Mar 13, 2025DOI: 10.1017/ice.2025.9Journal ArticleICHE

    Written by: Bryan SchneiderKelly M PercivalAnna M RhinehartJared FryeDeanna L McDanelKevin L BeboutLukasz D WeinerSarah A AuerbachAmy M DowdenDilek IncePatrick Kinn

    Find these authors on Roon

    DI
    Dr. Dilek Ince
    Transplant/Immunocompromised States · UI

    Summary

    BACKGROUND: Concerns about penicillin-cephalosporin cross-reactivity have historically led to conservative prescribing and avoidance of cephalosporins in patients with penicillin allergy labels, potentially causing suboptimal outcomes. Recent evidence suggests a lower risk of cross-reactivity, prompting a reassessment of alert systems.OBJECTIVE: To assess the impact of limited penicillin cross-reactivity alerts on outpatient cephalosporin use and the incidence of adverse reactions in a healthcare setting.METHODS: This retrospective cohort study compared cephalosporin prescribing and adverse reactions in patients labeled as penicillin-allergic before and after limiting penicillin cross-reactivity alerts in the electronic medical record at a large academic medical center.RESULTS: Among 17,174 patients (8,131 pre- and 9,043 post-implementation), there was a statistically significant increase in outpatient cephalosporin prescribing by 8% (P < .001). The use of alternative antibiotic classes decreased. There was no statistically significant increase in adverse events pre- and post-implementation (0.036%-0.058%, P = .547), and no severe events were attributable to cross-reactivity. The alert modification reduced alerts by 92% (P < .001).CONCLUSION: The reduction of penicillin-cephalosporin cross-reactivity alerts was associated with increased cephalosporin use, without a significant increase in adverse reactions. This demonstrates that the practice is safe and decreases alert burden.
    DIDr. Dilek Ince

    Dr. Dilek Ince

    Infectious Disease · Transplant/Immunocompromised States
    University of Iowa
    dilek
    Iowa City, IA, USA